Medroxyprogesterone acetate supplementation diminishes the hypoestrogenic side effects of gonadotropin-releasing hormone agonist without changing its efficacy in endometriosis

What Was Tested

This randomized controlled trial paper looks at Goserelin in the context of endometriosis.

To examine the effects of concomitant use of goserelin and medroxyprogesterone acetate (MPA) in the treatment of endometriosis.

Who Took Part

The abstract describes 29 women taking part.

The age groups tagged for this paper are adults, women only.

Symptoms and side effects were monitored for a treatment period of 6 months and a follow-up period of 6 months.

Blood and urine samples were collected for the assessment of endocrine and biochemical parameters.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The women were allocated by chance, so the Goserelin group and the comparison group should start out alike.

As a double-blind Goserelin study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Goserelin could be set against what happens without it.

The methods mention a period of 6 months.

A second-look laparoscopy was performed 6 months after the treatment in 29 women.

What Was Measured

Topics PubMed links to this paper include Endometriosis, Estrogen Antagonists, Goserelin, Medroxyprogesterone Acetate and Sex Hormone-Binding Globulin.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Goserelin in 29 women in people with endometriosis over 6 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1996 (Fertility and sterility), a journal based in United States.

More context: the Goserelin compound page, Endometriosis research.